NOVOB On Other Exchanges
Symbol
Exchange
OTC US
Copenhagen
Mexico
Frankfurt
text size: T | T
Back to Snapshot
Company Description

Contact Info

Novo Allé

Bagsvaerd, 2880

Denmark

Phone: 45 44 44 88 88

Fax:

Novo Nordisk A/S, a healthcare company, engages in discovering, developing, manufacturing, and marketing pharmaceutical products and services. The company markets its products in approximately 180 countries. Strategy The key elements of the company’s strategy include expand leadership in diabetes; establish presence in obesity; pursue leadership in haemophilia; and expand leadership in growth disorders. Segments The company operates through two business segments, Diabetes and Obesity Care; and Biopharmaceuticals. Diabetes and Obesity Care This segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. Diabetes The company’s Xultophy NN9068 is a combination of insulin degludec and liraglutide in a once dailysingle injection and is used for the treatment of Type 2 diabetes. It has filed/regulatory approval. The company’s faster-acting insulin aspart NN1218 is a new formulation of insulin aspart intended to accelerate onset of action, with the potential for increased flexibility of dosing and is used for the treatment of Type 1 and 2 diabetes. It has filed/regulatory approval. The company’s Semaglutide NN9535 is a once-weekly GLP-1 analogue intended to offer the clinical benefits of a GLP-1 analogue with less frequent injections to people with type 2 diabetes. This product is in Phase 3 stage. The company’s OG217SC NN9924 is a long-acting oral GLP-1 analogue intended as a once-daily tablet treatment for people with type 2 diabetes. This product is in Phase 2 stage. The company’s OI338GT NN1953 is a long-acting basal insulin analogue intended to offer the clinical benefits of a basal insulin analogue in a once-daily tablet. This product is used for the treatment of Type 1 and 2 diabetes. This product is in Phase 2 stage. The company’s Anti-IL-21 T1D NN9828 is intended as a beta-cell preservation treatment for people who are newly diagnosed with type 1 diabetes. This product is in Phase 2 stage. The company’s Dual-agonist NN9709 is a GLP-1/GIP dual-agonist intended as a once-daily treatment for people with type 2 diabetes. This product is in Phase 2 stage. The company’s LAI287 NN1436 is a long-acting basal insulin analogue intended for once-weekly dosing. This product is used for the treatment of Type 1 and 2 diabetes and is in Phase 1 stage. The company’s Mealtime NN1406 is a liver-preferential mealtime insulin analogue and is used for the treatment of Type 1 and 2 diabetes. This product is in Phase 1 stage. The company’s OI320GT NN1957 is a long-acting basal insulin in an oral formulation intended as a once-daily tablet treatment and is used for the treatment of Type 2 diabetes. This product is in Phase 1 stage. The company’s PYY 1562 NN9748 is an appetite-regulating hormone, peptide tyrosine, for the treatment of diabetes and is used for the treatment of Type 2 diabetes. This product is in Phase 1 stage. Obesity The company’s Semaglutide NN9536 is a long-acting GLP-1 analogue intended as a once-daily treatment for obesity. This product is in Phase 2 stage. The company’s AM833 NN9838 is a novel amylin analogue intended as a once-weekly treatment for obesity. This product is in Phase 1 stage. The company’s G530L NN9030 is a novel glucagon analogue which, in combination with liraglutide, is intended for the treatment of obesity. This product is in Phase 1 stage. The company’s PYY 1562 NN9747 is an appetite-regulating hormone, peptide tyrosine, which, alone or in combination with semaglutide, is intended for the treatment of obesity. This product is in Phase 1 stage. In 2015, the company launched Saxenda product to treat obesity in United States. This product is also available in Denmark, Italy, and Canada. Biopharmaceuticals This segment covers the therapy areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Haemophilia The company’s N9-GP NN7999 is a glycopegylated long-acting recombinant coagulation factor IX intended to offer prophylaxis and treatment of bleeds. This product is u

Page 12Next Page
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

NOVOB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NOVOB.
View Industry Companies
 

Industry Analysis

NOVOB

Industry Average

Valuation NOVOB Industry Range
Price/Earnings 14.4x
Price/Sales 4.8x
Price/Book 13.0x
Price/Cash Flow 11.4x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NOVO NORDISK A/S-B, please visit www.novonordisk.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.